Literature DB >> 30859279

[Kinase inhibitors in oncology : What is new?]

K Riedmann1, F Bassermann2,3, P J Jost1,4.   

Abstract

Kinase inhibitors are now among the most important drugs in targeted therapy and are used in particular for the treatment of different tumor entities. Since many kinase inhibitors inhibit various tyrosine kinases efficiently but not specifically, they are often characterized by their versatile use in a wide variety of entities and diseases. The diverse use of this group of drugs, as well as the challenge of their side-effect profile, continues to make kinase inhibitors the subject of numerous clinical studies. The following article provides an overview of recent new approvals in the field of kinase inhibitors and shows their importance for oncological therapy.

Entities:  

Keywords:  Carcinoma, non-small-cell lung; Leukemia, myeloid; Molecular targeted therapy; Protein kinase inhibitors, adverse effects; Protein-tyrosine kinases

Mesh:

Substances:

Year:  2019        PMID: 30859279     DOI: 10.1007/s00108-019-0577-8

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  17 in total

1.  Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.

Authors:  Meletios A Dimopoulos; Alessandra Tedeschi; Judith Trotman; Ramón García-Sanz; David Macdonald; Veronique Leblond; Beatrice Mahe; Charles Herbaux; Constantine Tam; Lorella Orsucci; M Lia Palomba; Jeffrey V Matous; Chaim Shustik; Efstathios Kastritis; Steven P Treon; Jianling Li; Zeena Salman; Thorsten Graef; Christian Buske
Journal:  N Engl J Med       Date:  2018-06-01       Impact factor: 91.245

2.  Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

Authors:  Solange Peters; D Ross Camidge; Alice T Shaw; Shirish Gadgeel; Jin S Ahn; Dong-Wan Kim; Sai-Hong I Ou; Maurice Pérol; Rafal Dziadziuszko; Rafael Rosell; Ali Zeaiter; Emmanuel Mitry; Sophie Golding; Bogdana Balas; Johannes Noe; Peter N Morcos; Tony Mok
Journal:  N Engl J Med       Date:  2017-06-06       Impact factor: 91.245

3.  Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.

Authors:  Jorge E Cortes; Dong-Wook Kim; Javier Pinilla-Ibarz; Philipp D le Coutre; Ronald Paquette; Charles Chuah; Franck E Nicolini; Jane F Apperley; H Jean Khoury; Moshe Talpaz; Daniel J DeAngelo; Elisabetta Abruzzese; Delphine Rea; Michele Baccarani; Martin C Müller; Carlo Gambacorti-Passerini; Stephanie Lustgarten; Victor M Rivera; Frank G Haluska; François Guilhot; Michael W Deininger; Andreas Hochhaus; Timothy P Hughes; Neil P Shah; Hagop M Kantarjian
Journal:  Blood       Date:  2018-03-22       Impact factor: 22.113

4.  Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.

Authors:  M E Gorre; M Mohammed; K Ellwood; N Hsu; R Paquette; P N Rao; C L Sawyers
Journal:  Science       Date:  2001-06-21       Impact factor: 47.728

5.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

Authors:  Brian J Druker; François Guilhot; Stephen G O'Brien; Insa Gathmann; Hagop Kantarjian; Norbert Gattermann; Michael W N Deininger; Richard T Silver; John M Goldman; Richard M Stone; Francisco Cervantes; Andreas Hochhaus; Bayard L Powell; Janice L Gabrilove; Philippe Rousselot; Josy Reiffers; Jan J Cornelissen; Timothy Hughes; Hermine Agis; Thomas Fischer; Gregor Verhoef; John Shepherd; Giuseppe Saglio; Alois Gratwohl; Johan L Nielsen; Jerald P Radich; Bengt Simonsson; Kerry Taylor; Michele Baccarani; Charlene So; Laurie Letvak; Richard A Larson
Journal:  N Engl J Med       Date:  2006-12-07       Impact factor: 91.245

Review 6.  Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.

Authors:  Ellen Weisberg; Paul W Manley; Sandra W Cowan-Jacob; Andreas Hochhaus; James D Griffin
Journal:  Nat Rev Cancer       Date:  2007-05       Impact factor: 60.716

7.  Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.

Authors:  Weiguo Zhang; Marina Konopleva; Yue-xi Shi; Teresa McQueen; David Harris; Xiaoyang Ling; Zeev Estrov; Alfonso Quintás-Cardama; Donald Small; Jorge Cortes; Michael Andreeff
Journal:  J Natl Cancer Inst       Date:  2008-01-29       Impact factor: 13.506

8.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Authors:  Stephen G O'Brien; François Guilhot; Richard A Larson; Insa Gathmann; Michele Baccarani; Francisco Cervantes; Jan J Cornelissen; Thomas Fischer; Andreas Hochhaus; Timothy Hughes; Klaus Lechner; Johan L Nielsen; Philippe Rousselot; Josy Reiffers; Giuseppe Saglio; John Shepherd; Bengt Simonsson; Alois Gratwohl; John M Goldman; Hagop Kantarjian; Kerry Taylor; Gregor Verhoef; Ann E Bolton; Renaud Capdeville; Brian J Druker
Journal:  N Engl J Med       Date:  2003-03-13       Impact factor: 91.245

9.  Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Authors:  Jean-Charles Soria; Yuichiro Ohe; Johan Vansteenkiste; Thanyanan Reungwetwattana; Busyamas Chewaskulyong; Ki Hyeong Lee; Arunee Dechaphunkul; Fumio Imamura; Naoyuki Nogami; Takayasu Kurata; Isamu Okamoto; Caicun Zhou; Byoung Chul Cho; Ying Cheng; Eun Kyung Cho; Pei Jye Voon; David Planchard; Wu-Chou Su; Jhanelle E Gray; Siow-Ming Lee; Rachel Hodge; Marcelo Marotti; Yuri Rukazenkov; Suresh S Ramalingam
Journal:  N Engl J Med       Date:  2017-11-18       Impact factor: 91.245

10.  Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial.

Authors:  Tim H Brümmendorf; Jorge E Cortes; Cármino Antonio de Souza; Francois Guilhot; Ladan Duvillié; Dmitri Pavlov; Karïn Gogat; Athena M Countouriotis; Carlo Gambacorti-Passerini
Journal:  Br J Haematol       Date:  2014-09-08       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.